Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Phase 3

Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Destruction of Kidney Stones With Laser

NCT05916963 · tracked via the Priya Life Science France tracker
Phase
Phase 3
Started
2024-01-04
Last updated
2025-11-24

Condition(s) studied

Kidney Stone

Investigational drug(s) / intervention(s)

Furosemide 40 mg →

Furosemide 40 mg: Injection of 40 mg of Furosemide during 10 minutes after the end of the flexible ureteroscopy for destruction of kidney stones with laser.

Study summary

In view of the positive results of the numerous studies conducted on forced diuresis after extra-corporeal lithotripsy, the investigators chose to evaluate forced diuresis by injection of Furosemide associated with intravenous hydration, which has never before been the subject of a specific analysis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Patients ≥ 18 years old and \< 80 years old * With the need to perform a flexible ureteroscopy with destruction of the kidney stones with laser * Participants covered by or entitled to social security * Written informed consent obtained from the participant * Ability for participant to comply with the requirements of the study Exclusion Criteria: * Persons covered by articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant women, parturients, nursing mothers, persons deprived of their liberty by judicial or administrative decision, minors, and persons subject to a legal protection measure: guardianship or trusteeship) * Contra-indication to Furosemide: * Hyper-sensitivity to the active substance or one of the excipients * Hyper-sensitivity to Sulfonamide * Renal failure with oligo-anuria refractory to Furosemide * Hypokalemia \< 3,5 mmol/L * Severe hyponatremia * Hypovolemia with or without hypotension or dehydration * Ongoing hepatitis, hepatic insufficiency severe and hepatic encephalopathy * Patient having Furosemide as usual treatment * Patient requiring an injection of Aminoside or Vancomycin before or during the procedure * Participation in other interventional research with an investigational drug or medical device

Primary outcome measure(s)

  • Rate of stone free patients — At 3 months
    Rate of stone-free patients 3 months after a flexible ureteroscopy for renal stone laser destruction, evaluated on the low dose abdomino-pelvic CT-Scan. A centralized review of the images will be performed by two specialized radiologists, in a blind and crossed way to allow a homogenization of the results

Trial sites (9)

FacilityCityRegionStatus
CHU d'Angers Angers France Recruiting
Hospices Civils de Lyon Lyon France Recruiting
CHU de Nice Nice France Recruiting
CHU de Nîmes Nîmes France Recruiting
CHU de Rennes Rennes France Recruiting
CHU de Rouen Rouen France Recruiting
CHU de Toulouse Toulouse France Recruiting
Clinique La Croix du Sud Toulouse France Recruiting
CHRU de Tours Tours France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05916963 on ClinicalTrials.gov ↗ ← All trials in France